Analysts Set Teleflex Incorporated (NYSE:TFX) Price Target at $148.00

Teleflex Incorporated (NYSE:TFX) has earned a consensus rating of “Hold” from the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $148.00.

A number of equities research analysts recently issued reports on TFX shares. Piper Sandler upgraded shares of Teleflex from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $140.00 to $160.00 in a research report on Monday, June 8th. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research report on Wednesday, June 24th. Raymond James Financial reaffirmed an “outperform” rating and set a $150.00 price objective on shares of Teleflex in a research note on Friday, May 8th. Wells Fargo & Company raised their price objective on shares of Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Finally, Bank of America upgraded shares of Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 target price for the company in a research note on Monday, April 13th.

Teleflex Price Performance

Shares of TFX stock opened at $131.10 on Thursday. The stock’s fifty day simple moving average is $130.86 and its 200 day simple moving average is $120.90. Teleflex has a one year low of $100.18 and a one year high of $139.67. The firm has a market cap of $5.80 billion, a price-to-earnings ratio of -5.75, a P/E/G ratio of 0.98 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.03.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.18. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The firm had revenue of $548.30 million during the quarter, compared to analyst estimates of $536.91 million. During the same period in the prior year, the company posted $1.44 earnings per share. The business’s revenue for the quarter was up 32.3% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, analysts expect that Teleflex will post 6.7 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Monday, May 25th were issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend was Friday, May 22nd. Teleflex’s dividend payout ratio (DPR) is currently -5.96%.

Hedge Funds Weigh In On Teleflex

Institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC grew its holdings in shares of Teleflex by 478.1% during the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock worth $287,603,000 after purchasing an additional 1,956,811 shares during the last quarter. Irenic Capital Management LP bought a new position in shares of Teleflex in the first quarter valued at about $104,061,000. Norges Bank acquired a new position in Teleflex during the 4th quarter worth about $66,076,000. Wolf Hill Capital Management LP acquired a new position in Teleflex during the 4th quarter worth about $47,405,000. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Teleflex by 123.9% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 660,800 shares of the medical technology company’s stock worth $80,855,000 after acquiring an additional 365,663 shares during the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.